Iovance Biotherapeutics shares rose 31.48% on Tuesday to finish at $14.45 after the company raised its full-year 2026 revenue outlook to $410 million-$420 million from $350 million-$370 million. The new range represents growth of 55.9% to 60% from the $263 million in revenue reported in 2025 and was supported by a record second quarter, sustained demand for Amtagvi and Proleukin, and manufacturing and operating efficiencies. Iovance previously reported record second-quarter product revenue of $99.3 million, including $91 million from Amtagvi, and expanded its authorized treatment-center network to approximately 100 locations while remaining on track to reach at least 110 by the end of 2026. Interim President and CEO Frederick Vogt said patient demand and the manufacturing schedule provide visibility into third- and fourth-quarter revenue, while lifileucel advances through registrational programs for additional solid-tumor indications. HC Wainwright raised its price target to $20 from $9 and maintained a buy rating, while TD Cowen increased its target to $16 from $10 and said Amtagvi revenue could reach $490 million in 2027. Goldman Sachs previously assigned a $15 target and a buy rating. Iovance is scheduled to report third-quarter 2026 results in early November.